Skip to Main Content
  • About
    • Staff
    • Board of Directors
    • Member Directory
  • Membership
    • Membership Benefits
    • Membership FAQ
    • Join NEC
  • Issues
    • Diversity & Inclusion
    • Energy & Environment
    • Financial Services
    • Healthcare
    • Higher Education
    • Housing
    • Technology & Innovation
    • Trade
    • Transportation & Infrastructure
    • Partnerships for Talent Pipeline Directory
  • Programs
    • Rising Stars Network
    • New England Council Fellows Program
    • Inside the Corner Office
    • Celebrating 100 Years
  • News
  • Events
    • Upcoming Events
    • Past Events
    • 2025 Centennial Celebration
    • Washington Leaders’ Conference
    • Politics & Eggs
    • Sponsorship Opportunities
  • Contact
  • About
    • Staff
    • Board of Directors
    • Member Directory
  • Membership
    • Membership Benefits
    • Membership FAQ
    • Join NEC
  • Issues
    • Diversity & Inclusion
    • Energy & Environment
    • Financial Services
    • Healthcare
    • Higher Education
    • Housing
    • Technology & Innovation
    • Trade
    • Transportation & Infrastructure
    • Partnerships for Talent Pipeline Directory
  • Programs
    • Rising Stars Network
    • New England Council Fellows Program
    • Inside the Corner Office
    • Celebrating 100 Years
  • News
  • Events
    • Upcoming Events
    • Past Events
    • 2025 Centennial Celebration
    • Washington Leaders’ Conference
    • Politics & Eggs
    • Sponsorship Opportunities
  • Contact

News

Oct 3, 2024Blog | Member News, Healthcare

U.S. FDA approves Eli Lilly’s drug for eczema

Reuters

The United States Food and Drug Administration (FDA) has approved New England Council member Eli Lilly and Company’s eczema drug for use in adults and children above 12 years of age. The drug, an injectable medicine branded Ebglyss, will be available in the next few weeks, according to the company.

The FDA’s approval was based on three studies including over 1,000 patients with moderate-to-severe eczema who were unable to manage their symptoms with topical medicines or other systemic treatments, Eli Lilly said.

Unlike some other eczema drugs on the market, Ebglyss can be dosed once-monthly, which is “viewed as attractive by experts and likely also patients,” Jefferies analyst Lucy Codrington stated last year.

The New England Council commends Eli Lilly and Company for its efforts in creating new and innovative medicine to help improve the lives of patients.

Read more via Reuters.

Council Related News
Read Article Blog | Member News, Technology & Innovation

Amazon celebrates opening of $300M Charlton robotics fulfillment center

Read Article Blog | Member News, Energy & Environment

Eversource brings “Main Streets” event to help bring Connecticut businesses affordable energy efficiency upgrades

Read Article Blog | Member News, Higher Education

University of New England joins global entrepreneurship network

Read Article Blog | Member News, Higher Education

Framingham State University museum receives largest donation in 50-year history

Read Article Blog | Member News, Healthcare

Point32Health hires new CEO

View Related News

©2025 New England Council
All rights reserved.

Privacy Policy Website Design by Jackrabbit

Boston Office

98 North Washington Street
Suite 303
Boston, MA 02114

(617) 723-4009

necouncil@newenglandcouncil.com

Washington Office

1411 K Street, NW
Suite 700
Washington, D.C. 20005

(202) 547-0048

necouncil@newenglandcouncil.com

Website Design by Jackrabbit